In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OncoMed Pharmaceuticals, Inc.

http://www.oncomed.com

Latest From OncoMed Pharmaceuticals, Inc.

Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work

After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.

Commercial Leadership

J.P. Morgan Day Two: Playing Up Potential In The Year Ahead

Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.

Business Strategies Deals

Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T

The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.

Companies Strategy

Surrozen Inks First Partnership With BI For Wnt-Targeted Retinopathy Candidate

German pharma takes global rights to preclinical bispecific antibody, while Surrozen will focus on Phase I candidates for inflammatory bowel disease and alcoholic hepatitis.

Deals Business Strategies
See All

Company Information

UsernamePublicRestriction

Register